Literature DB >> 9798822

Interpretation of cost-effectiveness analyses.

D K Owens.   

Abstract

Mesh：

Year:  1998        PMID： 9798822      PMCID： PMC1497852          DOI： 10.1046/j.1525-1497.1998.00211.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  8 in total

1.  Economic foundations of cost-effectiveness analysis.

Authors:  A M Garber; C E Phelps
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

2.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

Review 3.  The effectiveness of cost-effectiveness analysis in containing costs.

Authors:  N A Azimi; H G Welch
Journal:  J Gen Intern Med       Date:  1998-10       Impact factor: 5.128

4.  Technology assessment and cost-effectiveness analysis: misguided guidelines?

Authors:  C D Naylor; J I Williams; A Basinski; V Goel
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

5.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.

Authors:  A Gafni; S Birch
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

6.  Tentative guidelines for using clinical and economic evaluations revisited.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

7.  Economic assessments of medical practices and technologies.

Authors:  M C Weinstein
Journal:  Med Decis Making       Date:  1981       Impact factor: 2.583

8.  Screening for hypertension.

Authors:  B Littenberg; A M Garber; H C Sox
Journal:  Ann Intern Med       Date:  1990-02-01       Impact factor: 25.391
  8 in total
  69 in total

Review 1.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

2.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

Review 3.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09

5.  Random vs. nonrandom mixing in network epidemic models.

Authors:  Gregory S Zaric
Journal:  Health Care Manag Sci       Date:  2002-04

6.  Fluoroscopic percutaneous brush cytology, forceps biopsy and both in tandem for diagnosis of malignant biliary obstruction.

Authors:  Johannes Boos; Raphael J Yoo; Jennifer Steinkeler; Gamze Ayata; Muneeb Ahmed; Ammar Sarwar; Jeffrey Weinstein; Salomao Faintuch; Olga R Brook
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

Review 7.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  Crohn's disease: Cost-effectiveness of reducing radiation in Crohn's disease.

Authors:  Lena B Palmer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

9.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Cost-effectiveness of a faith-based lifestyle intervention for diabetes prevention among African Americans: A within-trial analysis.

Authors:  Elizabeth C Rhodes; Eeshwar K Chandrasekar; Shivani A Patel; K M Venkat Narayan; Thomas V Joshua; Lovoria B Williams; Lucy Marion; Mohammed K Ali
Journal:  Diabetes Res Clin Pract       Date:  2018-09-28       Impact factor: 5.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.